
United Kingdom · Research startup
Refeyn is an innovative company founded in 2018 as a spinout from Oxford University, specializing in mass photometry.
Funding reportedLast round: Series A
Refeyn is an innovative company founded in 2018 as a spinout from Oxford University, specializing in mass photometry.
This bioanalytical technology allows for the precise measurement of single molecules in their native, unlabeled state in solution. Headquartered in Oxford, UK, with additional offices in the US, Europe, Asia, and Japan, Refeyn aims to make its technology accessible to the global scientific community. The company's flagship product, the Refeyn mass photometer, is a compact analytical device designed for rapid mass analysis. It features automated software for efficient data processing and is capable of detecting molecular masses of single particles. Refeyn's technology is widely used in the life sciences sector, particularly in academic institutions and biopharmaceutical companies, for applications such as vector analytics, protein-protein interactions, and antibody aggregation analysis. With a strong focus on innovation, Refeyn is transforming biomolecular characterization and advancing bioanalytics.
Funding, as reported
Refeyn filed one raise, $214K in all. Filings say how much was sold and to how many investors; they never name the investors.
What they build
Known for
health carebiotherapeutic developmentbiotechnology researchsingle molecule measurementmass calibration standardsoligomeric state determinationcalibrantselectromedicalgmp compliancerapid dilution microfluidicscapsid loading analysislabel-free analysishospital & health carebiomolecular analyticsmedicalprotein-protein interactions
Built with from their website
Azure DevopsQtAtlassianOpticStudioPositGitHubGemCSSLiDARAtlassian Confluence
ETQ Reliance QMSLinkedIn LearningPyTorchApple Business ManagerNetSuiteKnowBe4Twilio SendGrid Email Marketing CampaignsSourceTree
Add your raise, your deck and your story, and put Refeyn in front of investors. Or tell us what we have wrong.